Η CURIUM ΑΝΑΚΟΙΝΏΝΕΙ
Η CURIUM ΑΝΑΚΟΙΝΏΝΕΙ ΌΤΙ ΟΙ ΠΡΏΤΟΙ ΑΣΘΕΝΕΊΣ ΣΤΗΝ ΕΛΛΆΔΑ ΈΛΑΒΑΝ ΈΝΕΣΗ ΜΕ PYLCLARI® - ΈΝΑΝ ΚΑΙΝΟΤΌΜΟ ΙΧΝΗΘΈΤΗ PET 18F-PSMA ΠΟΥ ΕΝΔΕΊΚΝΥΤΑΙ ΣΕ ΑΣΘΕΝΕΊΣ ΜΕ ΚΑΡΚΊΝΟ ΤΟΥ ΠΡΟΣΤΆΤΗ
16 nov. 2023 05h14 HE | Curium US LLC
ΠΑΡΙΣΙ, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Η Curium, παγκόσμιος ηγέτης στην πυρηνική ιατρική, ανακοίνωσε σήμερα ότι σε συνεργασία με τον αποκλειστικό διανομέα της SYN Innovation Laboratories στην...
Celcuity+Logo.jpg
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
13 nov. 2023 07h05 HE | Celcuity Inc.
Received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC) Entered into a...
arvinas_logoART_lg.jpg
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07 nov. 2023 07h00 HE | Arvinas Inc.
– Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – –...
arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
02 nov. 2023 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Transparency Market Research
Prostate Cancer Minimally Invasive Surgery Market Size is Envisioned to Grow at a CAGR of 3.6% and reach USD 3.9 billion by 2031|Report by TMR
01 nov. 2023 13h00 HE | Transparency Market Research
Wilmington, Delaware, United States, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. The global prostate cancer minimally invasive surgery market stood at US$ 2.9 billion in 2022...
Celcuity+Logo.jpg
Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
01 nov. 2023 07h05 HE | Celcuity Inc.
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
arvinas_logoART_lg.jpg
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
22 oct. 2023 07h00 HE | Arvinas Inc.
– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors...
arvinas_logoART_lg.jpg
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
18 oct. 2023 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
15 oct. 2023 18h07 HE | Arvinas Inc.
NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
15 oct. 2023 18h05 HE | Arvinas Inc.
NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant...